Clinical Trials Logo

Hyperlipoproteinemias clinical trials

View clinical trials related to Hyperlipoproteinemias.

Filter by:

NCT ID: NCT05305664 Active, not recruiting - Clinical trials for Hyperlipoproteinemia(a)

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

Start date: August 19, 2022
Phase: Phase 3
Study type: Interventional

Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established cardiovascular disease currently undergoing lipoprotein apheresis in Germany on a weekly schedule.

NCT ID: NCT05260411 Recruiting - Hyperlipidemia Clinical Trials

A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Start date: January 26, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled phase # clinical study evaluating the efficacy and safety of AK102 Q6W in patients with primary hypercholesterolemia and mixed hyperlipidemia.

NCT ID: NCT05256654 Active, not recruiting - Dyslipidemias Clinical Trials

A Study of LY3561774 in Participants With Mixed Dyslipidemia

PROLONG-ANG3
Start date: July 20, 2022
Phase: Phase 2
Study type: Interventional

This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.

NCT ID: NCT05255458 Recruiting - Hyperlipidemia Clinical Trials

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Start date: November 4, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the long-term efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.

NCT ID: NCT05255094 Recruiting - Hyperlipidemia Clinical Trials

A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Start date: November 3, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled phase Ⅲ clinical study evaluating the efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.

NCT ID: NCT05163587 Completed - Hyperlipidemias Clinical Trials

Composite Flour and Its Antdiabetic Potential

Start date: March 26, 2021
Phase: N/A
Study type: Interventional

A low glycemic multigrain flour for chapattis will be made from grains and cereals that are easily available in Pakistan. The nutritional profile and composition of test flour will be checked through proximate analysis method determined by AOAC. GI of test flour will be determined by comparing it with a reference food. The participants will be fed reference food i.e., 50gm glucose dissolved in 250ml water and test food serving having 50gm of available carbohydrates separately after an overnight fast. Finger prick method will be used to determine blood glucose levels at 0,15, 30, 45, 90 minutes. Trapezoidal rule will be used to determine iAUC and GI and GL will be determined by using standard formulas. Efficacy of test flour will be checked by human clinical trial. Control group will be fed chapatis made from test flour for 90 days. Anthropometry, body composition and biochemical measures including HbA1c, blood glucose (fasting and random) and lipid profile will be analyzed pre- and post-intervention and differences in their readings will be compared.

NCT ID: NCT05095480 Completed - Hyperlipidemias Clinical Trials

Effect of Red Yeast Rice Beside Statin on Lipid Profile

Start date: March 1, 2019
Phase: Phase 4
Study type: Interventional

We conducted a triple-blind clinical trial on 92 patients in 2019. They were randomly divided into a control group of 49 patients and a treatment group of 43 patients. Treatment group received Lesstat and placebo group received the same color tablets

NCT ID: NCT05090111 Completed - Clinical trials for NASH - Nonalcoholic Steatohepatitis

A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia

Start date: December 1, 2021
Phase: Phase 1
Study type: Interventional

A Randomized Study of ALG-055009 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses in Healthy Volunteers and Subjects with Hyperlipidemia

NCT ID: NCT05087823 Completed - Clinical trials for Cardiovascular Diseases

The Mixed Meal Challenge Study

Start date: November 2, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess sample collection conditions for various dietary challenges (fat, sugar, and mixed) and determine the optimal fasting and post-meal sample collection time points for future studies on a larger group of individuals. Study participants will attend three study visits where they take part in lipid, glucose, and mixed meal challenges. At each of the three visits, participants will provide venous blood samples and a urine sample before consuming the test meal and will provide 6 additional venous finger blood samples post-meal.

NCT ID: NCT05078736 Completed - Hyperlipidemias Clinical Trials

Effects of Moderate Intensity Intermittent and Moderate Intensity Continuous Training on Hyperlipdemia

Start date: August 30, 2021
Phase: N/A
Study type: Interventional

This project will be a Randomized control trial conducted to check the effects of moderate intensity intermittent training versus moderate intensity continuous training on indices of cardio-metabolic health in women with hyperlipidemia, duration will be of 5 weeks, purposive sampling data technique, will be done, subject following eligibility criteria from milestone gym Sialkot, will randomly allocated in two groups via lottery method, baseline assessment will be done, Group A participants will receive baseline treatment along with moderate intensity intermittent training, and Group B participants will receive baseline treatment along with moderate intensity continuous training. Pre and post intervention assessment will include lipid profile test and Vo2 max rating of perceived exertion (RPE), and post data will be analyzed by using SPSS version 25.